Esta página se tradujo automáticamente y no se garantiza la precisión de la traducción. por favor refiérase a versión inglesa para un texto fuente.

Proof-of-concept for Use of Transcutaneous Spinal Stimulation (TSS) With the ExaStim® Stimulation System in Adults With Chronic Ischemic Stroke (EXA2611)

29 de octubre de 2026 actualizado por: Casa Colina Hospital and Centers for Healthcare

Proof-of-concept for Use of Transcutaneous Spinal Stimulation (TSS) With the ExaStim® Stimulation System in Chronic Stroke Population

The goal of this clinical trial is to learn about the safety, tolerability, and feasibility of ExaStim transcutaneous electrical stimulation combined with task-specific rehabilitation, and to characterize changes in arm function in adults with chronic unilateral ischemic stroke. The main questions it aims to answer are:

  • Does 12 weeks of ExaStim stimulation combined with structured, task-specific rehabilitation improve arm function?
  • What are the safety, tolerability, and feasibility of ExaStim use in individuals with chronic stroke?

Participants will:

  • Complete a 12-week intervention period combining ExaStim transcutaneous electrical stimulation with structured, task-specific rehabilitation
  • Undergo clinical assessments and outcome testing baseline, week 4, week 8, week 12, and week 17 (follow-up)
  • Monitor and report pain and quality of life via Visual Analog Scales (VAS) and questionnaires throughout the 17-week study duration

Descripción general del estudio

Descripción detallada

Primary exploratory clinical objective: To characterize change in upper extremity motor impairment following 12 weeks of ExaStim stimulation combined with structured, task-specific rehabilitation in individuals with chronic stroke.

Secondary objective: To characterize safety, tolerability, and feasibility of ExaStim use in individuals with chronic stroke. Exploratory objectives include describing immediate on/off-stimulation differences in dexterity and persistence of observed changes at Week 17; the design is not intended to establish causal effectiveness.

Additional exploratory outcomes:

  • Change from baseline to Weeks 4, 8, and 17 in each of FMA-UE, ARAT, BBT, 9HPT, MAL, and SIS.
  • Change from Week 12 to Week 17 in each of FMA-UE, ARAT, BBT, 9HPT, MAL, and SIS.
  • Descriptive comparison of the group mean FMA-UE change from baseline to Week 12 with the exploratory 4.25-point reference.
  • Change from baseline to Week 12 in Modified Ashworth Scale scores.

The FMA-UE screening range of 20-50 is supported by its use in chronic stroke neuromodulation studies, including VNS-REHAB (Dawson et al., 2021) and the TRICEPS protocol (Baig et al., 2025). This eligibility precedent does not establish a clinically meaningful change threshold for ExaStim. Page, Fulk, and Boyne (2012) reported clinically important differences of 4.25-7.25 points in chronic stroke with mild-to-moderate impairment, depending szon the therapist-rated anchor. Accordingly, 4.25 points will be used only as an exploratory reference when describing observed changes. Group mean change will summarize the overall magnitude of change, while individual changes and baseline scores will show participant variability. Neither a group mean nor an individual change of ≥4.25 points will define study success or a clinically meaningful responder in this proof-of-concept study.

Feasibility will be summarized using screening and enrollment counts, retention through Week 17, completed sessions out of 24 planned, sessions delivering at least 45 minutes of stimulated rehabilitation, actual stimulation minutes, interruptions, and reasons for missed visits or discontinuation. Twice-weekly paired BBT and 9HPT measurements will describe unstimulated trajectories and within-visit changes with stimulation. These summaries supplement the synopsis endpoints without changing their hierarchy. Feasibility measures will be reported descriptively with their denominators; no additional operational success thresholds are specified for this proof-of-concept study.

Tipo de estudio

Intervencionista

Inscripción (Estimado)

5

Fase

  • No aplica

Contactos y Ubicaciones

Esta sección proporciona los datos de contacto de quienes realizan el estudio e información sobre dónde se lleva a cabo este estudio.

Estudio Contacto

Copia de seguridad de contactos de estudio

  • Nombre: Daniel Humphrey, PT, DPT, NCS
  • Número de teléfono: 3036 609-596-7733
  • Correo electrónico: dhumphrey@casacolina.org

Ubicaciones de estudio

    • California
      • Pomona, California, Estados Unidos, 91767
        • Casa Colina Hospital and Centers for Healthcare
        • Contacto:
        • Contacto:
        • Sub-Investigador:
          • Emily Rosario, PhD
        • Investigador principal:
          • Yannick Darmon, PT, PhD
        • Sub-Investigador:
          • Daniel Humphrey, PT, DPT, NCS

Criterios de participación

Los investigadores buscan personas que se ajusten a una determinada descripción, denominada criterio de elegibilidad. Algunos ejemplos de estos criterios son el estado de salud general de una persona o tratamientos previos.

Criterio de elegibilidad

Edades elegibles para estudiar

18 años a 75 años (Adulto, Adulto Mayor)

Acepta Voluntarios Saludables

No

Géneros elegibles para el estudio

Todos

Descripción

Inclusion Criteria:

  1. Subject must have a documented diagnosis of a singular unilateral ischemic stroke event confirmed by radiology report.
  2. Participant is in the chronic stage of neurological recovery, defined as at least 6 months after the unilateral ischemic stroke event.
  3. Subject is aged 18-75 years
  4. In the investigators or qualified clinician's judgment, the subject must possess sufficient global cognitive capacity to understand and follow study-related instructions, actively participate in task-specific rehabilitation, and provide informed consent. Cognitive capacity will be supported by the subject's ability to follow a three-step command and demonstrate orientation to person, place, time, and situation (4/4)
  5. Subject must have a Fugl-Meyer Assessment-Upper Extremity (FMA-UE) score between 20 and 50 (inclusive) at screening.
  6. Subject must be able to commit to participating in a 17-week study, and be willing to comply with study instructions, agree to make all office and therapy appointments, and complete the entire course of the study
  7. Subject must be deemed medically stable for intensive physical rehabilitation and transcutaneous electrical stimulation, supported by formal written clearance from their primary care physician or managing neurologist.
  8. Subject must be able to understand the study, provide informed consent, and complete the applicable HIPAA authorization using IRB-approved procedures. Literacy alone is not an exclusion. IRB-approved accessible consent methods may be used when needed, while the investigator confirms the participant's own understanding, decision-making capacity, and ability to meet study communication requirements.

Exclusion Criteria:

  1. Active implanted medical device for electrical stimulation
  2. Index stroke is hemorrhagic or involves the brainstem, cerebellum, or thalamus, as confirmed by neuroimaging or medical records.
  3. Other internal metallic objects of unknown or foreign origin (unidentifiable surgical implants, shrapnel, bullet fragments, etc.)
  4. Botox injections to the upper limb(s) in prior 3 months
  5. Severe spasticity, MAS grade >3 (grade 4 only; grade 3 is not excluded by this criterion) in any of the following muscles: shoulder abductors, shoulder flexors, elbow flexors/extensors, wrist flexion, forearm supination or pronation, or finger flexors.
  6. Subject scores <20 or >50 points on the FMA-UE.
  7. BMI > 40.0 (morbid obesity)
  8. Acute medical conditions under active treatment that would contraindicate standard rehabilitation including open wounds, unhealed bone fractures, peripheral neuropathies or painful musculoskeletal dysfunction
  9. Subjects who are pregnant or planned pregnancy during the study. Participants of childbearing potential must agree to effective contraception for the duration of participation.
  10. Allergy to hydrogel, silicone, latex or other product materials
  11. Compromised skin in the area for electrode contact (back of neck and/or hip area)
  12. Uncontrolled cardiopulmonary disease or hypertension
  13. Presence of ongoing dysphagia or aspiration difficulties.
  14. Significant sensory impairments. Subjects who score below a 6 out of 12 on the sensory subscale (section H) of the Fugl Meyer Assessment will be excluded.
  15. Other symptoms that would prohibit use or cause discomfort from stimulation such as hypersensitivity.
  16. History of more than one stroke episode
  17. Severe contractures of upper extremity(s)
  18. Severe receptive and/or expressive aphasia limiting communication and understanding of device and interventions
  19. History of uncontrolled epilepsy or seizures
  20. Unmanaged depression, psychiatric disorders or ongoing substance abuse
  21. Participation in another clinical trial that may interfere with this study

Plan de estudios

Esta sección proporciona detalles del plan de estudio, incluido cómo está diseñado el estudio y qué mide el estudio.

¿Cómo está diseñado el estudio?

Detalles de diseño

  • Propósito principal: Viabilidad del dispositivo
  • Asignación: N / A
  • Modelo Intervencionista: Asignación de un solo grupo
  • Enmascaramiento: Ninguno (etiqueta abierta)

Armas e Intervenciones

Grupo de participantes/brazo
Intervención / Tratamiento
Experimental: ANEUVO ExaStim Stimulation System

Week 0 includes one baseline assessment session and two to three parameter optimization sessions. Participants will attend 2 rehabilitation sessions per week for 12 weeks, for a total of 24 sessions. Each session will provide ~60 minutes of rehabilitation, including at least 45 minutes of active stimulation delivered concurrently with therapeutic activity. The therapist will select activities according to participant goals, affected-arm capacity, movement quality, fatigue, pain, and cardiovascular tolerance. Each session will emphasize repeated practice, functional strength or functional practice. Missed sessions will be rescheduled within the 12-week period if appropriate.

Separate assessment visits occur in Weeks 4, 8, 12, and 17 and may last approximately one to two hours with rest breaks.

The final evaluation is scheduled for Week 17. All assessments will use the same participant-specific baseline date as the time reference, and actual visit dates and intervals will be recorded.

¿Qué mide el estudio?

Medidas de resultado primarias

Medida de resultado
Medida Descripción
Periodo de tiempo
Fugl-Meyer Assessment for Upper Extremity - Motor Score (FMA-UE)
Periodo de tiempo: Initial assessment at enrollment, re-assessment at weeks 4, 8, 12, and 17

The Fugl-Meyer Upper Extremity Assessment is a 66-point stroke-specific scale measuring sensorimotor recovery across reflexes, synergies, isolated movements, wrist stability, hand function, and coordination. Each item is scored from 0 to 2 based on performance completeness and compensation. Changes exceeding the minimal clinically important difference (typically 4 to 10 points) reflect meaningful gains in motor control and functional independence.

Initial assessment at enrollment, re-assessment at weeks 4, 8, 12, and 17

Medidas de resultado secundarias

Medida de resultado
Medida Descripción
Periodo de tiempo
Action Research Arm Test (ARAT)
Periodo de tiempo: Initial assessment at enrollment, re-assessment at weeks 4, 8, 12, and 17

The Action Research Arm Test (ARAT) is a 57-point, 19-item observational assessment measuring upper extremity functional capacity and dexterity across grasp, grip, pinch, and gross movement subscales. Each task is scored from 0 to 3 based on completion time, movement quality, and compensation patterns. A score change exceeding the minimal clinically important difference (typically 6 to 10 points) indicates meaningful improvement in real-world arm and hand function.

Initial assessment at enrollment, re-assessment at weeks 4, 8, 12, and 17
Box-and-Blocks Test (BBT)
Periodo de tiempo: Initial assessment at enrollment, at the start of each treatment session, and during re-assessment visits at weeks 4, 8, 12, and 17

The Box and Block Test measures unilateral gross manual dexterity by recording the number of one-inch wooden blocks a patient can transport over a partition from one compartment to another in 60 seconds. The scoring system simply counts the total number of successfully transferred blocks per hand, with multiple blocks carried simultaneously counting as a single point. An increase in score exceeding the minimal detectable change (typically around 6 or more blocks for stroke populations) indicates a true, statistically significant improvement in hand transport speed and unilateral functional capacity.

Initial assessment at enrollment, at the start of each treatment session, and during re-assessment visits at weeks 4, 8, 12, and 17
9-Hole Peg Test (9HPT)
Periodo de tiempo: Initial assessment at enrollment, at the start of each treatment session, and during re-assessment visits at weeks 4, 8, 12, and 17

The Nine-Hole Peg Test (9HPT) measures manual dexterity and finger-movement speed by recording the total seconds required for a patient to place and subsequently remove nine pegs into a board. Scoring is based on timing (seconds per trial), where lower times indicate better performance, or converted to "pegs per second" for rate-based analysis. A change in score exceeding the minimal detectable change (typically a reduction of several seconds or roughly 15 to 20% from baseline) indicates a statistically significant improvement in fine motor speed and coordination.

Initial assessment at enrollment, at the start of each treatment session, and during re-assessment visits at weeks 4, 8, 12, and 17
Visual Analog Scale (VAS) for pain
Periodo de tiempo: Initial assessment at enrollment, at the end of each treatment session, and during re-assessment visits at weeks 4, 8, and 12

The Visual Analog Scale (VAS) measures subjective symptom intensity, such as pain, using a continuous horizontal line anchored by "no symptom" at one end and "worst imaginable symptom" at the other. Patients mark their perceived level, and the score is quantified from 0 to 10, where higher numbers reflect greater symptom severity. A score change exceeding a 2 point change indicates a clinically meaningful improvement or worsening of the patient's symptom experience.

Initial assessment at enrollment, at the end of each treatment session, and during re-assessment visits at weeks 4, 8, and 12

Otras medidas de resultado

Medida de resultado
Medida Descripción
Periodo de tiempo
Motor Activity Log (MAL)
Periodo de tiempo: Initial assessment at enrollment, re-assessment at weeks 4, 8, 12, and 17

The Motor Activity Log (MAL) is a structured, semi-structured clinical interview where stroke survivors rate their actual daily arm use in terms of Amount of Use (AOU) and How Well (HW) they perform 30 real-world functional tasks. Each item is scored on a 0-to-5 ordinal scale, ranging from 0 (not used at all) to 5 (used as well as before the stroke), with final scores derived from the average of all items. A change in score exceeding the minimal clinically important difference (typically around 1.0 to 1.1 points for either subscale) indicates a meaningful, real-world translation of laboratory motor gains into spontaneous, daily spontaneous arm use.

Initial assessment at enrollment, re-assessment at weeks 4, 8, 12, and 17
Stroke Impact Scale (SIS)
Periodo de tiempo: Initial assessment at enrollment, re-assessment at weeks 4, 8, 12, and 17

The Stroke Impact Scale (SIS) is a patient-reported outcome measure evaluating health-related quality of life across eight domains, including strength, hand function, ADLs, mobility, communication, emotion, memory, and participation. Each item is scored on a 1-to-5 ordinal scale, which is then transformed into a standardized 0-to-100 scale per domain, where higher scores reflect better recovery and fewer stroke-related limitations. A score change exceeding the minimal clinically important difference (typically ranging from about 3 to 17 points depending on the specific domain) indicates a statistically reliable and meaningful improvement in the patient's perceived recovery and daily well-being.

Initial assessment at enrollment, re-assessment at weeks 4, 8, 12, and 17
Modified Ashworth Scale (MAS)
Periodo de tiempo: Initial assessment at enrollment, re-assessment at week 12

Modified Ashworth Scale (MAS), it grades spasticity and muscle hypertonia on a 6-point ordinal scale from 0 (no increase in tone) to 4 (rigid limb in flexion or extension). A decrease in score indicates a reduction in passive resistance and muscle hypertonia, reflecting successful management of spasticity.

Initial assessment at enrollment, re-assessment at week 12

Colaboradores e Investigadores

Aquí es donde encontrará personas y organizaciones involucradas en este estudio.

Investigadores

  • Director de estudio: Emily Rosario, PhD, Casa Colina Hospital and Centers for Healthcare

Publicaciones y enlaces útiles

La persona responsable de ingresar información sobre el estudio proporciona voluntariamente estas publicaciones. Estos pueden ser sobre cualquier cosa relacionada con el estudio.

Publicaciones Generales

Fechas de registro del estudio

Estas fechas rastrean el progreso del registro del estudio y los envíos de resultados resumidos a ClinicalTrials.gov. Los registros del estudio y los resultados informados son revisados ​​por la Biblioteca Nacional de Medicina (NLM) para asegurarse de que cumplan con los estándares de control de calidad específicos antes de publicarlos en el sitio web público.

Fechas importantes del estudio

Inicio del estudio (Estimado)

18 de noviembre de 2026

Finalización primaria (Estimado)

18 de mayo de 2027

Finalización del estudio (Estimado)

18 de noviembre de 2027

Fechas de registro del estudio

Enviado por primera vez

29 de octubre de 2026

Primero enviado que cumplió con los criterios de control de calidad

29 de octubre de 2026

Publicado por primera vez (Actual)

4 de noviembre de 2026

Actualizaciones de registros de estudio

Última actualización publicada (Actual)

4 de noviembre de 2026

Última actualización enviada que cumplió con los criterios de control de calidad

29 de octubre de 2026

Última verificación

1 de octubre de 2026

Más información

Términos relacionados con este estudio

Plan de datos de participantes individuales (IPD)

¿Planea compartir datos de participantes individuales (IPD)?

NO

Información sobre medicamentos y dispositivos, documentos del estudio

Estudia un producto farmacéutico regulado por la FDA de EE. UU.

No

Estudia un producto de dispositivo regulado por la FDA de EE. UU.

Sí

producto fabricado y exportado desde los EE. UU.

Sí

Esta información se obtuvo directamente del sitio web clinicaltrials.gov sin cambios. Si tiene alguna solicitud para cambiar, eliminar o actualizar los detalles de su estudio, comuníquese con register@clinicaltrials.gov. Tan pronto como se implemente un cambio en clinicaltrials.gov, también se actualizará automáticamente en nuestro sitio web. .

Suscribir